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INTRODUCTION 
 
Hemophilia is a disorder of coagulation. Hemophilia A is due to 
deficiency of clotting factor VIII and Hemophilia B is due to deficiency of 
factor IX. Both are inherited as X-linked, so males usually exhibit the disease 
and females are carriers. 
Prevalence of Hemophilia A is 1in 5,000 to 10,000 male births and that 
of Hemophilia B is 1 in 20,000 to 34,000 births. Hemophilia A accounts for 
about 80% cases of hemophilia and hemophilia B around 20%. Hemophilia C is 
due to deficiency of factor XI and unlike other Hemophilias, it is autosomal and 
is also the rarest of the three. 
In hemophilia patients plasma does not contain clotting factors in 
sufficient amount, required for coagulation in case of any injury or breach in the 
blood vessel. In case of any injury the clot formed by platelet plug is not stable 
and cannot maintain hemostasis, so patient bleeds for a long time continuously 
or intermittently. Patients with hemophilia do not bleed intensely but for a 
longer duration than the normal individual, it may last days to weeks in case of 
severe deficiency. Bleeding into closed spaces such as joint spaces, 
intramuscular compartments and intracranial space is debilitating and fatal if 
not treated timely. 
The treatment of Hemophilia has seen a vast amount of changes since 
1960s to recent times from plasma and cryoprecipitate transfusion, fraction of 
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Factor VIII and factor IX to recombinant factor VIII and Factor XI synthesis. 
The success of treatment is limited due to transfusion related viral transmission 
in plasma derived substrates and development of inhibitors in patients treated 
with pure Factor VIII and IX replacements from recombinant therapy. 
Transfusion related viral infections like HIV, HCV and HBV infections were a 
major hazard of treatment of Hemophilia in later part of 20
th
 century. The 
infections show a decreasing trend due to efficient screening and viral 
inactivation of blood products. HBV prevalence has reduced significantly 
because of vaccination in risk groups and general properties. 
The study intend to evaluate the prevalence of important transfusion 
related viral infections like Hepatitis B, Hepatitis C and HIV infection in 
hemophilia and to evaluate the clinical profile and quality of life(QOL) of 
hemophilia patients using functional assessment tools  in Coimbatore Medical 
College Hospital. 
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AIM OF THE STUDY 
 To evaluate the clinical profile of patients with hemophilia admitted in 
medical wards and attending Hemophilia Clinic of Coimbatore Medical 
College Hospital. 
 To find the prevalence of HIV, HCV and Hepatitis B in hemophiliacs. 
 To assess the quality of life using functional assessment tool 
FUNCTIONAL INDEPENDENCE SCORE IN HEMOPHILIA (FISH) 
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REVIEW OF LITERATURE 
 
Hemophilia is a group of coagulation disorders in which the blood fails 
to clot normally because of a qualitative or quantitative deficiency of clotting 
factors. 
The factors most frequently found deficient in hemophilia are factors 
VIII and IX, whose genes are located in the X chromosomes and, when 
defective, causes the X-linked recessive traits hemophilia A and B. The 
incidence of hemophilia A is 1 in 5,000-10,000 live births and that of 
hemophilia B is 1 in 60,000. The incidence of hemophilia in India is around 1 in 
5000 males. It has been estimated that in India about 1300 children with 
hemophilia are born every year (1). According to expectation India is having 
nearly 100,000 hemophiliacs. However, according to the most recent survey by    
the World Federation of Hemophilia, according to data provided by the 
Hemophilia Federation of India (HFI) about 13,500 patients are registered (3). 
Rare coagulation disorders due to deficiencies of other factors, including 
prothrombin, Factor V, Factor VII, Factor X, Factor XI, Factor XIII, and 
fibrinogen shows autosomal recessive pattern of  inherited (8). 
With the availability of cryoprecipitates and plasma derived clotting 
factor concentrates since 1970s, the treatment of hemophilia has improved a lot 
in developed countries. Patients with hemophilia can live a normal life and have 
a normal life span in developed countries, but in developing countries like India 
the adequate treatment of hemophilia is still a major problem, as less than 5% 
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have the proper education about the disease, resource and access to treatment 
(4,5). 
In 1960s the average life expectancy for severe hemophiliacs was less 
than 2 decades, and with severe crippling morbidity and devastating from joint 
bleeding or intracranial hemorrhage (6, 7). 
HISTORY: 
The description of hemophilia like disease is seen in ancient literature 
dating back to second century. The earliest medical person to describe the 
disease was Abulcasis. In the 10
th
 century he described families in which males 
died of severe bleeding after only minor trauma (9). Dr. John Conrad Otto, an 
American physician, accounted about ―a hemorrhagic disposition existing in 
certain families‖ in which he called the affected male ―bleeders‖ in 1803 (10). 
Dr. Otto reckoned that the disease was inherited and that it seen mostly boys 
and was transmitted by carrier women. 
Hemophilia was seen in few members of European royal families and 
thus in sometimes called ‗the royal disease‘ or ‗blue blood disease‘. It is 
believed the Empress Victoria passed the mutation of Hemophilia B (11, 12) to 
one of her sons Leopold and, through some of her daughters, to various royal 
families across Europe, including the royal families of Russia, Spain and 
Germany. 
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PATHOPHYSIOLOGY: 
Coagulation is the process by which blood forms firm fibrin clots in the 
injured vessel walls. It is the vital part of   hemostasis, where the injured vessel 
wall is covered by platelets plug and firm fibrin mesh to cease the bleeding and 
initiates the repair injured vessel. Disorders of coagulation lead to an increased 
risk of hemorrhage or thrombosis (13).  Inactive clotting factors in the 
circulation get activated via two pathways namely intrinsic and extrinsic 
pathways to form a firm fibrin from soluble fibrinogen via tightly controlled 
chain of enzymatic reactions. The intrinsic pathway is the most complex, 
requiring exposure of negatively charged collagen fibres inside the damaged 
endothelium for activation of factor XII, which further activates factor XI, 
followed by factor IX and  factor VIII, and then the common pathway (14,15). 
The extrinsic pathway is initiated when factor VII comes in contact with tissue 
factor released into the circulation from breached endothelium. This initiates the 
common pathway of cascade by activating factor X with the presence of  factor 
V , then prothrombin to thrombin, and lastly forms firm fibrin mesh from 
fibrinogen (16, 17). Extrinsic pathway is most prominent and constitutes for 
80% of function. Intrinsic pathway and extrinsic pathway is assessed by aPTT 
and PT respectively. 
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FIGURE 1: SCHEMATIC REPRESENTATION OF COAGULATION CASCADE 
          
People with factor VIII  deficiency manifest with Hemophilia A, 
clinically presenting with prolonged bleeding with or without trauma. Lab 
investigation show a prolonged aPTT , a normal PT, bleeding time, and platelet 
count. If Factor VIII can be estimated in the plasma it will be low. 
Persons with factor IX deficiency manifests with Hemophilia B, which is 
seen less commonly with similar clinical features, lab and physical findings as 
does hemophilia A. An aPTT estimation measures factor XII, factor XI, factor 
X, factor IX, factor V, and prothrombin function. 
GENETICS:          
The factor VIII gene is situated on the long arm of X-chromosome 
(Xq28) [18]. Factor VIII protein is synthesized by glomerular, tubular and 
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vascular endothelium and the sinusoidal cells of the liver (19). The gene 
encoding for factor IX protein is situated on the long arm of X-chromosome at 
q26.3-27.1 position (20). 
 
FIGURE 2 :SCHEMATIC REPRESENTATION OF FACTOR VIII 
GENE ON THE LONG ARM OF X CHROMOSOME 
 
A male receives his only X-chromosome from his mother; the son of a 
healthy carrier female with the defective gene will have 50% probability of 
inheriting the defective genes from his mother and to have disease. For a female 
to inherit the disease an extreme rarity, for which she must have to receive two 
defective X-chromosome, one from her mother  and one from her father.  Hence 
Hemophilia is more common among males than compared to females. One 
more possibility for female carriers to manifest the disease is due to abnormal 
lyonisation of the X-chromosome. Another possibility of a female manifesting 
the disease is the patient with the Turner syndrome with this defective gene. 
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About 40% of severe hemophilia A results from a major inversion of a section 
of the tip of the long arm of X-chromosome , one breakpoint  of which is 
situated with intron 22 of the factor VIII gene (21) and  is the most commonly  
associated  with severe hemophilia A. 
 
FIGURE 3: INHERITANCE PATTERN OF HEMOPHILIA 
About ten useful polymorphisms have been described with the factor IX 
gene (22). In contrast to hemophilia A, spontaneous mutations are low (23), and 
most of the hemophilia B patients have family history of bleeding disorder. 
According to a 1998 hemophilia B database, which includes information about 
mutations and clinical features of as many as 1700 patients (24);. 
CLINICAL   FEATURES 
The severity of bleeding symptom in hemophilia A patients linearly 
correlates with the level of functional factor VIII in plasma (25). Nearly 50 to 
60% of Hemophilia A patients are severely symptomatic with factor VIII 
coagulate activity in the blood less than 1% of normal. Severe hemophilia A 
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will manifest with frequent episodes of spontaneous bleeding into joints, 
muscular tissues, soft tissues and other internal organs. Factor VIII activity in 
the range of 1 to 5% of the normal in 25 to 30% of patients results in moderate 
hemophilia A. In the moderate form, abnormal bleeding is generally related to 
minor traumatic injuries. The rest of the patients have 6 to 30% of normal factor 
VIII activity and manifests with mild hemophilia A. In the mild form of the 
disease bleeding occurs only in the event of significant trauma or surgery (26). 
TABLE 1. CLINICAL CLASSIFICATION OF HEMOPHILIA 
 
             
The coinheritance of the factor V Leiden or other prothrombotic factors 
mutation in patients with severe Hemophilia A, delays the first symptomatic 
hemorrhagic event (28). There is no family history of abnormal bleeding in at 
least one-third of all hemophiliacs (29). This proportion is consistent with the 
Haldane hypothesis, which predicted that maintenance of constant frequency of 
 11 
 
a genetic disorder in the population would essentially require about one-third of 
cases resulting from spontaneous de-novo mutation. 
Infants rarely manifest disease because they are insulated from trauma 
(30); hematomas are first noticed when children become active, and 
hemarthroses rarely seen until they begin to crawl or walk. In few instances 
disease is occult until patients reach adolescence. 
HEMARTHROSIS 
Hemarthrosis or joint bleeding is the most frequent, painful and 
debilitating manifestation of the disease. Hemarthrosis accounts for nearly 74% 
of bleeding episodes in severely affected Hemophilia A patients (46). Few 
patients present with a characteristic warm, tingling sensation prior to the onset 
of hemarthrosis called as aura. The earliest definite symptom is excruciating 
pain. Examination reveal muscle spasm and limitation of joint mobility 
associated with swelling and warmth. Usually, single joint is involved at a time, 
occasionally more than one joint at a time. Knee is most commonly involved 
followed by elbows, ankle, hip, wrist, shoulder. Hemarthrosis is more 
commonly seen in Hinge joints compared Ball and socket joints. Hemarthrosis 
usually starts when the child starts to crawl or walk. 
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The development of haemophilic arthritis occurs in three stages  
1. Acute haemarthrosis 
2. Chronic synovitis 
3. Degenerative arthritis. 
Acute Hemarthrosis recurs intermittently. With each episode, the 
synovium becomes more and more thickened and vascular. Which  predispose 
to subsequent synovial injury even with minimal activity.  These abnormally 
proliferating synovium fills up and distends the joints,  which keeps joint in 
swollen condition even in the absence of any bleeding; chronic proliferative 
synovitis (31). With the weakening of the periarticular supporting structures, 
predisposes the joint to recurrent  episodes of bleeding. Repeated  episodes of 
hemarthrosis with subchondral and synovial ischemia, result in progressive less 
of hyaline cartilage, especially at the margins of the joints. Disuse, diffuse 
demineralization of the involved bone occurs leading to the terminal stage of 
FIGURE 4: HEMARTHROSIS 
OF RIGHT KNEE JOINT 
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hemarthrosis called chronic hemophilic arthropathy (32). The term ―target 
joint‖ is used frequently in hemophilia care to describe a joint that had recurrent 
bleeding episodes. The definition of target joint varies, but a common definition 
is four bleeds into the same joint in a six-month time period. The most common 
target joints are the knees, ankles, and elbows. Once a target joint is  
established, there usually is persistent synovial thickening and joint effusion 
with limited range of motion. 
 
FIGURE 5: SHOWING VICIOUS CYCLE OF CHRONIC  
HEMOPHILIC ARTHROPATHY 
 
The radiological classification of hemophilic arthropathy. This scoring 
system includes radiologic changes of  osteoporosis, epiphyseal enlargement, 
joint space narrowing, subchondral irregularity, subchondral cyst formation, 
joint erosion, and deformity (33).  
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Arnold-Hilgartner classification 
is a grading system using plain 
radiograph for haemophilic 
arthropathy  
 stage 0: normal joint 
 stage I: no skeletal abnormalities, 
soft-tissue swelling is present 
 stage II: osteoporosis and 
overgrowth of the epiphysis, no 
cysts, no narrowing of the 
cartilage space 
 stage III: early subchondral bone 
cysts, squaring of the patella, widened notch of the distal femur or humerus, 
preservation of the cartilage space 
 stage IV: findings of stage III, but more advanced; narrowed cartilage space 
 stage V: fibrous joint contractures, loss of the joint cartilage space, extensive 
enlargement of the epiphyses with substantial disorganisation of the joint.  
MRI has superiority over standard radiography for assessment of early 
arthropathy.  
 A scoring system for magnetic resonance joint evaluation has also been  
reported (34) (Table 2). 
FIGURE 6: HAEMOPHILIC 
ARTHROPATHY ( LIKELY STAGE 
IV ) 
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TABLE 2. SCORING SYSTEM FOR HEMOPHILIC  
ARTHROPATHY USING MRI 
 
  SCORE                          ABNORMALITIES ON IMAGING 
     0                            None 
      I                        Minimal hemosiderin 
     II                  Large amount of hemosiderin and cartilaginous erosion 
     III                Cartilage destruction, bone erosion, subchondral cysts 
     IV                Osteoarthritis with or without ankylosis 
 
SUBCUTANEOUS AND INTRAMUSCULAR HEMATOMAS 
Large ecchymoses, subcutaneous and intramuscular hematomas are 
commonly seen in hemophilia A and B, which can spread along the facial 
planes to deeper tissues. At the site of origin, the tissue is hard, indurated, 
raised, and purplish black. From this center, the hemorrhage extends in all 
directions. Fever, leukocytosis and intense pains is seen in case of intramuscular 
and subcutaneous bleeding even without of any swelling or discoloration of the 
overlying skin. Bleeding in head and neck region can be life threatening 
because it may compromise the airway and major vessels (35). 
PSOAS AND RETROPERITONEAL HEMATOMAS 
Spontaneous bleeding into abdominal muscles and internal fascial spaces 
are commonly seen in hemophilia A and hemophilia B. Bleeding into iliopsoas 
muscle compartment causes intense and progressive pain and tenderness. If it 
occurs in right iliopsoas muscle, can mimic acute appendicitis. Involvement of 
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femoral nerve usually presents with pain or parasthesia in the anterior thigh. 
Psoas sign may be positive with the hip held in partial flexion. Paresthesias, 
partial or complete anesthesia, and ultimately, weakness or paralysis of 
extensors of the thigh may ensue. Bleeding into the peritoneum and 
retroperitoneal region is also seen often. CT scan may be useful in the diagnosis 
of these hematomas (36).  
 
FIGURE 7: ILIOPSOAS MUSCLE HEMATOMA    FIG 8: PROLONGED BLEEDING FROM CUT INJURY  
GASTROINTENSTINAL AND GENITOURINARY BLEEDING 
Bleeding from the oral cavity, especially the gum is common, so is 
bleeding from lips and the tongue. Severe epistaxis is reported in several 
patients. Deciduous teeth may be shed without excessive bleeding; however this 
bleeding may last for days in end. Bleeding from the gastrointestinal tract 
commonly arises from pathological areas like gastritis. Intussusception or 
intestinal obstruction may be a sign of intramural bleed. Incessant use of 
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NSAID for pain relief in Hemophiliacs lead to a five times higher incidence of 
peptic ulcer disease (47). 
Genitourinary bleeding is less common and may arise in the bladder or 
kidneys and usually persists for several days (37). 
MUCOUS MEMBRANE HEMORRHAGE: 
Bleeding from mucous membrane is a common symptom in hemophilia. 
Gum bleeding and bleeding from oral cavity are common and are due to bad 
oral hygiene and dental caries. Epistaxis and hemoptysis, usually results from 
local irritation or injury and local  structural pathologies involving the upper or 
lower respiratory tract. Use of cautery or nasal packing may follow intermittent 
or continuous bleeding due to exuviations or dislodgement of predicate clot on 
removal of packing. 
NEUROLOGIC MANIFESTATIONS: 
Intracranial hemorrhage is the most serious bleeding event in hemophilic 
patients. Bleeding may be ―spontaneous‖ but usually follows any trivial trauma. 
Symptoms usually start soon after trauma, but at times may be last as in case of 
subdural hematoma. Parenchymal bleeding or a subdural or epidural hematoma 
must be suspected in a hemophilic patient with unusual headaches. In case 
intracranial bleeding is suspected, the patient should be treated with factor VIII 
replacements as early as possible. Diagnostic workup, like CT scans or MRI 
studies, must be held back till treatments with factor replacements are initiated. 
Procedures like Lumbar puncture quiet safely even in case of severe hemophilic 
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patients without any replacement therapy, replacing factor VIII in the plasma to 
a level of about 50% of normal before the procedure is safer. Bleeding into the 
spinal canal is an uncommon neurologic complication in hemophilia but if 
occurs, it can lead to paraplegia. Epidural bleeding compressing upon the cord 
is much more common compared to bleeding within the spinal cord (48). 
 
FIGURE 9: INTRACRANIAL BLEED IN A CASE OF HEMOPHILIA 
TRAUMATIC BLEEDING 
Traumatic bleeding is a common reason for hospital admissions. Minor 
injuries are usually self limiting; larger injuries bleed disproportionally however 
and can persist for several days to weeks.  Sometimes, there is a delayed onset 
of hemorrhage from site of minor trauma which then becomes problematic. This 
occurs commonly following minor surgeries like dental extraction and 
tonsillectomy. surgeries in mild hemophilia. The processes of primary 
hemostasis are initially effective for a transient period and are overwhelmed by 
the bleeding tendency later on. 
Venipuncture is not safe in hemophiliacs if performed with sufficient 
skill, due to the elasticity of the veins. If venipuncture is traumatic, finger 
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pressure or a pressure dressing on the puncture site may cease the bleeding. 
Subcutaneous, intradermal and small intramuscular injections rarely produce 
hematoma if firm pressure is maintained for a minimum of 5 minutes. Large 
intramuscular injections are unsafe. 
Hemophilia does not appear to protect older patients from 
thromboembolic disorders (38) or atherosclerosis (39, 40). 
In recent times, prognosis in severe hemophilia has remarkably 
improved. With appropriate treatment with sterile and recombinant factor 
replacements, a nearly normal span of life can be expected and the debilitating 
sequelae of this disorder can be minimized.  
HEMOPHILIA B 
Hemophilia B clinically  it is difficult to distinguish from hemophilia A 
by clinically alone. It is a X-linked, recessive bleeding disorder characterized by 
reduce factor IX clotting activity. Aggeler et al and Biggs et al (49), in 1956 
reckoned the existence of one more X chromosomes-linked bleeding disorder 
that was clinically analogous to classic hemophilia. The defective coagulation 
factor was designated as Factor IX, and the disorder is called as Christmas 
disease or Hemophilia B. 
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DIAGNOSIS 
LABORATORY INVESTIGATION: 
        Routine hematologic examinations reveal no characteristic finding in 
hemophilia A. Anemia may be present in case of severe and frequent bleeding 
episodes. Neutrophilia may be seen in case of severe bleeding.   
 
TABLE 3: SCREENING TESTS FOR BLEEDING DISORDERS 
 
 
 
Activated partial thromboplastin time (aPTT) is prolonged in hemophilia 
A patients if the factor VIII level is less than 25% of normal plasma, however 
some aPTT reagents may be less sensitive and results may be normal incase of 
mild factor VIII deficiency (41).  
 Correction studies 
Correction or mixing studies using pooled normal plasma (PNP) will 
help to define whether prolonged coagulation times are due to factor deficiency 
or circulating anticoagulants of inhibitors. Correction studies with FVIII/FIX-
deficient plasma may be used to identify the particular deficiency if a factor 
assay is not available.   
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 FACTOR VIIIc ASSAY: 
Technique of assay of factor VIII is a simple. One-stage methods, two-
stage method and micro-method are suitable for diagnosis. The one-stage 
techniques are used most widely because of its simple procedure. They require 
either plasma from a known severe hemophiliac or artificial substrate plasma 
(42). Two-stage assays detect approximately 20% more factor VIII compared to 
one-sage methods (43). 
FACTOR VIIIAg (CAg) ASSAY: 
Highly specific assay using immune radiometric methods (immune 
radiometric assay) and ELISA techniques (44) are available to  for measurement 
of antihaemophilic factor A antigen (VIII:CAg). Immuno radiometric assay uses 
liquid and solid phase principles and both natural factor VIII antibodies and 
FIGURE 10: APPROACH TO 
ISOLATED PROLONGED 
APTT   
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monoclonal antibodies. ELISA techniques were more accurate than immune 
radiometric assay methods in a comparative study (45). The results of both of 
these techniques demonstrate the absence of factor VIIIAg in most severly 
affected hemophiliacs and has an appreciable correlate with factor VIIIc 
measurements in most patients. 
HEMOPHILIA B: 
Hemophilia must be differentiated from hemophilia A; clinically both 
the disease is indistinguishable, only method of differentiation is by laboratory 
method and assay of factor IX in plasma. Factor IX assay is done ELISA and 
immune radiometric methods. 
PRENATAL DIAGNOSIS AND CARRIER DETECTION: 
A meticulous and detailed family history is immense importance for 
carrier state detection (50). All female offspring of a hemophilic father have 
100% chance of being the carrier. If a know carrier for defective gene has a 
daughter, the daughter has a 50% probability of being a carrier. 
Carrier detection is of great importance when a daughter of a known 
carrier of the defective gene or a daughter of a hemophilic patient wants to 
become pregnant. If facilities for sophisticated carrier detection are not readily 
available, a careful family history must be taken and factor VIII & the von 
Willebrand factor (v WF) levels in plasma measured. The ratio of v WF factor 
VIII is high in carrier females compared to that of non-carriers; thus, measuring 
the ratio adds to test sensitivity. Carriers usually have a factor VIII level of less 
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than 50% to that of normal plasma. When these data combined with family 
history, the probability of a female being is carrier can be estimated(51, 52).  
However, the test results carry a significant error rate, and precise 
determination of the carrier state using the ratio of factor VIII to v WF is not 
fool proof. 
  The intron 22 inversion mutation of Factor VIII gene in carriers can be 
detected with the help of Southern blot technique. By this technique, analysis of 
the complete coding region can be done using gradient gel electrophoresis and 
single-stranded conformation polymorphism technology or restriction fragment 
length polymorphism (RFLP) analysis (50). 
Use of markers for RFLP is technically easier than direct sequencing of 
the factor VIII gene coding regions (53, 54). 
Prenatal diagnosis of hemophilia can be done easily nowadays. If a 
carrier female is pregnant, the sex fetus can be by chromosomal analysis of cells 
acquired by amniocentesis or by chorionic villus sampling at 16
th
 week and 10
th
 
week of pregnancy respectively. If the fetus is female 50% probability of 
carriers and rest being normal, carriers carry very remote chance of bleeding.  If 
the fetus is male, adequate amount of cells must be obtained to do DNA 
analysis by any of the above mentioned methods. In case of male fetus carrying 
defective gene, the decision on whether to continue the pregnancy to term 
should be left to the parents after they have been adequately counseled and 
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provided with relevant and proper information. Because, the severity of  
hemophilia is consistent  within that family members. 
TREATMENT 
Pain management: 
General principles of therapy for hemophilia A includes avoidance of 
aspirin, NSAIDs, and other drugs that interfere with function of platelet 
aggregation.  Paracetamol or COX-2 inhibitors such as celecoxib or etoricoxib 
can be used safely at lower doses. Patients must be educated about other 
analgesics containing aspirin or any other drugs interfering with platelet 
function. Intramuscular injections must be avoided. Opioids can be used safely 
for analgesia. Use of steroids are controversial. 
About Surgical procedures in hemophilia patients, it must be planned 
early part of the week to avoid ―weekend crises‖. Sufficient and surplus stores 
of factor VIII must be available in the pharmacy or blood bank to make sure of, 
rapid access of factor in case of any complications. Prophylactic factor 
replacement must be considered in case of severe hemophilia, to avoid acute 
hemorrhages and other complications like worsening of arthropathy. 
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TABLE 4 : STRATEGIES FOR PAIN MANAGEMENT IN 
HEMOPHILIA 
 
FACTOR VIII REPLACEMENT THERAPY: 
Factor replacement products can be recombinant or plasma derived. 
Plasma derived proteins carries the risk of   Hepatitis C and HIV infection. 
Bleeding episodes in hemophilia A patients can be treated by replacing 
factor VIII. Various plasma derived products are available to raise factor VIII to 
normal level. 
Factor VIII containing Fresh Frozen Plasma and cryoprecipitates were 
the only treatment option available in early days. A major drawback of plasma 
is, large volumes required be administered to attain and sustain even minimal 
factor VIII levels. The highest factor VIII level achievable with plasma 
transfusion is approximately 20% of normal, which is not always achievable or 
suffice for hemostasis. Cryoprecipitate contains about 80 U of factor VIII in 
each 10 ml, but each bag of cryoprecipitate must be pooled and the products 
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need to be stored in frozen condition. Several commercially available 
lyophilized factor VIII concentrates, using pooled cryoprecipitate from normal 
humans plasmas from about 2000-20,000 donors, are available and has minimal 
disadvantages compared to that of plasma and cryoprecipitate.  
Sterilization technique such as heating in solution, superheating to 80 C  
after lyophilization or exposing to detergent organic solvent are employed to 
sterilize factor VIII concentrates, these methods kill enveloped virus such as 
HIV, HBV and HCV but parvovirus and HAV cannot be killed by these 
methods (55, 56). But parvovirus infection is not seen in hemophilia a patients 
because parvovirus is transmitted by the cellular blood components. HAV is 
also not seen in patients receiving plasma-derived factor concentrates as it is 
killed by solvent-detergent techniques (57). 
Factor concentrated derived from plasma and sterilized by above 
mentioned methods are generally considered highly purified and safe from viral 
diseases unless there is any breakdown during manufacturing process. 
RECOMBINANT FACTOR VIII 
Factor VIII produced artificially by recombinant DNA techniques is 
readily available, which is safe and effective too. Newer factor VIII products 
are being manufactured without exposure to animal or human protein. These 
products were developed in wake of fear or transmission of new-variant 
Creutzfeldt-Jakob disease (CJD) disease by human blood products. This 
concern was raised by a single report of possible transmission of CJD to a 
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recipient patient who received a blood transfusion from a donor who later went 
on to develop new-variant CJD (58). 
DOSAGE OF FACTOR REPLACEMENT: 
One unit of factor VIII per ml of plasma is considered 100% of normal. 
Thus, the plasma volume of a 70-kg adult is approximately equivalent to 3500 
ml (5% x 70 kg = 3.5 kg = 3500g, approximately equivalent to 3500 ml).  To 
achieve normal factor VIII levels of 1 U/ml i.e., 100% 3500 U of factor VIII 
need to be given. This scenario is with assumption of a 100% recovery of the 
administered dose. After the   loading dose of factor VIII, further doses of factor 
VIII are based on a half-life of 8 to 12 hours. Thus, after a loading dose of 3500 
U of factor VIII, a dose of 1750 U could be given in 12-24 hour. FVIII should 
be infused  slowly as IV injection at a rate not exceeding 3 ml per minute in 
case of adults and 100 units per minute for young children 
The interval and amount of factor VIII to be infusion required depends 
upon the site and severity of bleed. Table 4 shows the recommended dosage of 
factor VIII for various types of bleeding episodes.  These doses have not been 
tested in any strict controlled randomized trials and recommendations changes 
among different centres. Due to the high cost of factor VIII, most centres prefer 
the lower  doses  (59). 
HEMOPHILIA-B: 
           The general principle for treatment of hemophilia B is same that of 
hemophilia A. The cornerstone of therapy of Christmas disease is factor IX 
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replacement. Prothrombin complex concentrates containing factor IX,  
prothrombin and other activated clotting factors derived from large pool of 
plasma obtained from thousands of donors was used before the advent of 
recombinant factor IX. Main disadvantage of prothrombin concentrate is cost, 
which is higher than recombinant factor IX. 
The dosage of factor IX is usually double that of factor VIII for 
hemophilia A, as the in vivo recovery is low due to binding of factor IX to some 
unknown elements in the vessel wall. 
Incidence of DVT and DIVC have been reported in several cases due 
contamination of activated components. Other complications of plasma derived 
factor transfusion are similar to hemophilia A. 
In current practice, two commonly employed  approaches for managing 
hemophiliacs are 
 On demand therapy – given during the bleeding episodes. 
 Prophylactic therapy 
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TABLE 5 :SUGGESTED PLASMA FACTOR PEAK LEVELS AND 
DURATION OF ADMINISTRATION IN HEMOPHILIA A AND B 
 
PROPHYLACTIC THERAPY: 
By the advent and availability of stable and safe recombinant factor VIII 
concentrates, prophylactic therapy for severe hemophilia A patients is feasible 
but cost is a major disadvantage in resource constraint countries.  
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FIGURE11: PROPHYLACTIC THERAPY 
There are currently two protocols in use for which there is a long-term data: 
 THE MALMO PROTOCOL:  Injections of 25-40 IU/kg, administered 
three times a week for those with hemophilia A and   twice a week for those 
with hemophilia B 
 THE UTRECHT PROTOCOL : Injections of 15-30 IU/kg, administered 
three times a week for those with hemophilia A and twice a week for those 
with hemophilia B 
In countries with significant  resource constraints, lower  doses of 
prophylaxis given more frequently (e.g., 10-15 IU/kg , 3 times per week) may 
be an effective option. 
Administration of prophylactic factor replacement therapy for severely 
affected hemophilia patients is recommended whenever such treatment is 
feasible and available. Patients for this therapy must be selected, based on their 
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reliability and ability to manage central venous catheter devices, since it is very 
important for its success(69,70). 
OTHER TREATMENT MODALITIES 
Fresh frozen plasma dosage: 
FFP is prepared by separating citrated plasma apart from whole blood 
and freezing it within 8 hours of collection of blood or by freezing citrated 
apheresis plasma within 6 hours of collection. FFP can be stored for a period up 
to 1 year, at a temperature of -18
o
 C or below. There is minimal loss of activity 
of the factors V and VIII when stored under  these conditions. Each ml of FFP 
contains about one unit of    coagulation factor activity. After thawing, FFP may 
be stored in the refrigerator for up to 24 hours before use. Each unit of FFP 
prepared from whole blood contains 200ml of plasma. Aphaeresis plasma may 
be packaged into 200- or 400-ml bags. At the dose of 10 to 15 ml/kg of plasma, 
it would constitute approximately 25 to 30 % replacement therapy for 
coagulation factors, although there is lesser recovery of some factors because of 
its diffusion into the extra vascular space(61,62). 
PLASMA FROZEN WITHIN 24 HOURS: 
         This is the plasma that has been stored in the refrigerator for up to 24 
hours before freezing. The constituents of this product are almost similar  to 
FFP except that factor VIII coagulant activity is reduced to 75% to that of the 
normal (63). If administered immediately after thawing, the factor VIII content 
 32 
 
of this product would be similar to that of an FFP unit stored for 24 hours after 
thawing. 
CRYOPRECIPITATE: 
Cryoprecipitate, is an super extract of FFP that is enriched with high-
molecular-weight plasma proteins. Cryoprecipitate is prepared by thawing one 
unit of FFP at 1
o
to  6
o
C. At these conditions, the high molecular weight proteins 
will remain as a precipitate, and the precipitated protein is centrifuge 
concentrated, and all except approximately 15 ml of supernatant is removed. 
The remaining 15 ml and the precipitate are refrozen. A bag of cryoprecipitate 
made from one unit of FFP (200-250ml) may contain 70–80 units of FVIII in a 
volume of 30–40 ml. Factor XIII and the high-molecular-weight multimers of 
vWF are the other constituents. As a fact cryoprecipitate  developed for the 
treatment of hemophilia A, but it is no longer the standard treatment of choice 
for the disease after the advent of less infectious alternatives like recombinant 
factor availability (62). 
HEMOPHILIA A MINOR BLEEDING: 
 
Desmopressin (DDAVP) can be used effectively in treatment of minor 
bleeding   episodes in hemophiliacs with baseline factor VIII levels more than 5 
U/dl, if patients have been previously responding to treatment. Side effects are 
seen if the total dose exceeds more than 24 µg. Administration by either 
parentral or intranasal route producers   significant increases in factor VIII and 
v WF levels. 
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DESMOPRESSIN:,( DDAVP)  
 
           In 1970s, when DDAVP (1-deamino-8-D-arginine vasopressin) used for 
other purposes they observed that there was an increase in factor VIII in the 
blood normal individuals. Subsequently they used this phenomenon to treat the 
factor VIII deficiency status i.e haemophilia A. Its usage limited only to mild to 
moderate hemophilics. For unknown cause it did not show any response in 
severe hemophilics. After injection of recommended dosage (0.3 µg/kg, body 
weight) especially to the mild to moderate hemophilics, factor VIII level was 
increased by 2 to 3 fold above baseline (64). An intranasal spray preparation is 
also available (150 µg in each nostril). 
It is given through intravenous route as infusion. It will take 30 to 60 
minutes to its response by increasing the factor VIII. Some time some patients 
with mild to moderate severity also will not respond to the DDAVP. Because of 
that reason for all patients prior testing is necessary to see the responsiveness 
especially before the bleeding episode to occur it can be used along with the 
blood products also especially when the factor VIII level is less than 0.5U/ml in 
the blood. The exact mechanism of action of the DDAVP in terms of increasing 
factor VIII is obscure. After using DDAVP repeatedly it has shown reduced 
responsiveness called as tachyphylaxis. In many patients, the responsiveness is 
reduced by 25% after the second dose. Subsequent doses may be even lessening 
the responsiveness further more (66). 
DDAVP can cause hyponatremia as it a potent antidiuretic. 
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FIBRINOLYTIC INHIBITORS: 
E AMINOCAPROIC ACID 
Epsilon Aminocaproic acid (EACA) is biochemically similar to the 
amino acid lysine, is a synthetic inhibitor of fibrinolysis. It inhibits plasminogen 
activation competitively. It is absorbed rapidly by oral and is excreted by the 
kidney. The oral dose of EACA is 6 grams QID. When it is used IV, a 5 gm 
loading dose must be infused over a period of 30 minutes to avoid hypotension. 
TRANEXAMIC ACID: 
Tranexamic acid is an analogy of aminocaproic acid and is similar 
pharmacological properties. It can be used orally 15 mg/kg as loading dose and 
30 mg/kg every 6 hours after. Anti-fibrinolytics are used as added therapy 
especially for bleeding in the mouth, nose etc and are of important value in 
adjunctive therapy during dental procedures. 
 
FIGURE 12: MECHANISM OF ACTION OF ANTIFIBRINOLYTICS 
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Untoward effects of the drug are formation of the thrombosis by 
inhibition of plasminogen activator and also cause reduction in the blood 
pressure, myopathy, GI discomfort, loose stools. The drug is contraindicated in 
patients with DIVC as it has potential to produce excessive blood clotting and 
hematuria because of risk of urinary tract obstruction by clot (65). 
REPLACEMENT OF FACTOR VIII FOR SURGICAL PROCEDURES: 
Normally, during surgical procedure there will be consumption of the 
clotting factors including the factor VIII. Every hemophilia patient is monitored 
the level of factor VIII level before, after and during the procedure. Before 
initiation of the surgical procedure step should be taken to normalize the factor 
VIII level in the blood. The normal level should be maintained up to 7-10 days 
after the surgery. Major surgeries like orthopedic procedures may require more 
than the normal level of factor VIII (77). 
Liver Transplantation 
          Liver transplantation holds the key of permanent treatment in hemophilia 
patients from the chronic debilitating disease. Successful liver transplantation in 
hemophiliacs, has resulted in cure of hemophiliac patients (71,72). 
Liver transplantation not only cures hemophilia but also is the treatment 
of choice for chronic hepatitis, which affects a large number of the 
hemophiliacs in later part of life. 
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GENE THERAPY 
Gene therapy for hemophilia offers an ideal approach for patients on 
prophylactic therapy. Gene therapy can be used prophylactically and as a 
permanent cure. Gene therapy trials in hemophilia patients consist, ex vivo 
transduction of human fibroblasts with a plasmid containing the factor VIII 
gene and implantation of the transduced fibroblast cells subsequently into 
patients. One more method of introducing the gene is by intravenous infusion of 
a retroviral vector containing the cDNA for factor VIII (74). No major side 
effects were seen in both the trials, but in both of the trials the expression of 
factor VIII levels in plasma were about 1% of the normal and persisted in 
plasma for a period ranging from month to 1 year. Factor VIII protein 
expression is difficult because it is large in size, it must be processed in the 
endoplasmic reticulum and Golgi bodies, for which chaperone proteins are 
essential for correct protein folding and other post-translational alterations (75. 
76). With the development of viral and non-viral gene transfer is very important 
for gene therapy. 
FACTOR VIII INHIBITORS 
Apart from transmission of viral diseases by plasma derived factor VIII 
concentrates therapy, the most important complication of hemophilia A and 
hemophilia B treatment is the development of specific inhibitors of factor VIII 
which are the neutralizing antibodies (73). The incidence of factor VIII 
inhibitors in severe hemophilia A patients is quiet large in number, it was about 
40% in patients with large deletion defects and 35% in patients with nonsense 
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mutations. The overall incidence of inhibitors formation in the whole 
hemophiliac population is about 20% on a long term followup. Factor VIII 
inhibitors are antibodies of IgG class and they are usually alloantibodies, 
autoantibodies also develop. Antibodies against the A2 and C domains of factor 
VIII are most common. the interactions of the  factor VIII with the other 
hemostatic components will be interfered by these antibodies(78). 
RISK FACTORS FOR DEVELOPMENT OF FACTOR VIII  
INHIBITORS 
Disease severity: 80% of hemophilia A patients with inhibitors have 
<1% factor VIII activity 
 Exposure to factor VIII concentrates: majority of high-titer inhibitors 
develop after 90 days of exposure to factor VIII 
 Genetic factors: 
 1.  Family history of inhibitor development 
             2.  Negative correlation with HLA Cw5 antigen 
             3.  Molecular defects: inversion and crossing-over defect in intron 22, 
gene deletions, and nonsense point mutations resulting in patients                        
without factor VIII antigen. 
 Method of purification of factor VIII concentrate 
Screening for inhibitors 
For children, inhibitors should be screened once every five exposure 
days until 20 exposure days, every 10 exposure days between 21 and 50 
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exposure days, and at least two times a year until 150 exposure days. For adults 
with more than 150 exposure days, apart from a 6-12 monthly review, any 
failure to respond to adequate factor concentrate replacement therapy in a 
previously responsive patient is an indication to assess for an inhibitor.  
Inhibitor measurement should also be done in all patients who have been 
intensively treated for more than five days, within four weeks of the last 
infusion(80).  
Inhibitors should also be assessed prior to surgery or if recovery assays 
are not as expected, and when clinical response to treatment of bleeding is sub-
optimal in the post-operative period.  
A low responding inhibitor is defined as an inhibitor level that is 
persistently < 5 BU/ml, whereas a high responding inhibitor is defined by a 
level ≥ 5 BU/ml. 
Presence of inhibitors must be suspected clinically when patient does not 
respond to conventional doses of factor VIII, diagnostic tests are essential to 
confirm. When plasma of hemophilia is mixed with plasma of normal 
individual in 1:1 ratio and incubated at 37°C for 1- 2 hour duration aPTT will 
be normal in absence of inhibitors, if aPTT is still prolonged presence of 
inhibitor must be suspected. The demonstration of the inhibitor to be specific 
for factor VIII differentiates it from other clotting factor inhibitor like, the lupus 
anticoagulant, and nonspecific inhibitors. Commonly used assay for a factor 
VIII inhibitor is Bethesda assay. In Bethesda assay, the patient's plasma is 
diluted such that, when the plasma is mixed with an equal volume of normal 
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pooled human plasma and incubated for 2 hours, the factor VIII activity in the 
mixture is decreased by 50 percent (82). 
 
TABLE 6:  TREATMENT OF INHIBITORS IN   HEMOPHILIA A 
 
MANAGEMENT OF HEMOPHILIA WITH INHIBITORS 
IMMUNE TOLERANCE  INDUCTION THERAPY(ITI) 
In patients with severe hemophilia A by immune tolerance induction 
(ITI) therapy eradication of inhibitors is often possible. Before ITI therapy, 
high-responding patients should avoid FVIII products to allow inhibitor titres to 
fall and to avoid persistent anamnestic rise. As noted, some patients may 
develop an anamnestic response to the inactive FVIII molecules in APCC as 
well(81) .Optimal regimen (product or dose) for ITI remains to be defined. An 
international trial comparing 50 IU/kg three times a week to 200IU/kg daily was 
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recently stopped due to safety concerns (higher number of intercurrent bleeds) 
in the low-dose arm pending detailed analysis and interpretation of the data   
Response to ITI may be less favourable in patients with moderate/mild 
hemophilia 
BYPASSING AGENTS 
Recombinant activated FVII (rFVIIa) and plasma-derived activated 
prothrombin complex concentrate(APCC), are suggested as alternative therapies 
to factor VIII (haemophilia A) or IX (haemophilia B) for individuals who no 
longer respond to these treatments because they develop inhibitory antibodies. 
Instead of replacing the missing factor, they go around (or bypass) the factors 
those are blocked by the inhibitor to help the body to form an normal clot 
RECOMBINANT ACTIVATED rFVIIa – DOSAGE 
Dosage of rFVIIa = body weight( in kg) *90µg/kg body weight 
To repeat every 2-3 hours until hemostasis achieved And  half-life of the  
rFVIIa was about  2.3 hours in adults, and  it is shorter in children. 
PLASMA-DERIVED ACTIVATED PROTHROMBIN COMPLEX 
CONCENTRATE(APCC) FEIBA – DOSAGE 
In case of major bleed 40 – 50 IU/Kg body  weight 
In case of significant bleed , the dose can be repeated at 12 hours interval 
To avoid tranexamic acid while on FEIBA in view of increased risk of 
thrombosis 
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THERAPY RELATED INFECTIONS 
Transmission of HCV, HBV, HIV and other virus is a known 
complication in patients treated by plasma derived factor concentrates. HIV was 
the leading cause of death before the advent of viral inactivation and 
recombinant factors. HCV and HBV infections are seen in 88% of patients 
treated with cryoprecipitates between 1980 and 1985. These infections tends to 
diminish the quality  of life in Hemophiliac adult patients in terms of  ‗physical 
capacity‘, ‗pain‘, ‗general health‘ and  ‗mental health‘. 
PHYSIOTHERAPY: 
Physiotherapy Exercises and sports activities like cricket, tennis, golf 
and baseball can be advised and generally considered safe in hemophiliacs. It 
prevents progression of arthropathy and improves muscle strength. Sports 
activities like football, rugby and basketball which requires contact must be 
avoided. 
HEMOPHILIA QUALITY OF LIFE ASSESSMENT 
Hemophilia can interfere with  individual´s life due to its complexity, 
effects and associated co morbidities. Due to chronic nature of disease, it can 
lead to physical and/or psychological changes of the patients. When considering 
the aspects mentioned, the investigation for the quality of life (QOL) in the 
perception of the individual with the hemophilia is necessary. The quality of life 
is understood as the patients´ perception of their well-being in several areas, 
including the physical, emotional, mental, social and behavioral(82-84). 
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Several hemophilia-specific scores are available to measure joint 
impairment and function, including activities and participation. These include: 
■ Impairment: 
Clinical: WFH Physical Examination Score (aka Gilbert score), Hemophilia 
Joint Health Score (HJHS) 
Radiological:  Pettersson score, MRI, and ultrasound scores 
Activity:  Haemophilia Activities List (HAL), Paediatric Haemophilia 
Activities List (PedHAL), Functional Independence Score in Hemophilia 
(FISH) 
■  Health-related quality of life:  
( HaemoQol, Canadian Hemophilia Outcomes: Kids‘ Life 
Assessment Tool [CHO-KLAT] 
                                  
  
 43 
 
MATERIALS AND METHODS 
 
SOURCE OF STUDY: 
Data consists of primary data collected by the principal investigator 
directly after obtaining proper consent from the patients/guardians of 
HEMOPHILIA patients attending  HEMOPHILIA TREATMENT CENTRE  
and  those  getting admitted at medicine wards  in Coimbatore Medical College 
Hospital.   
DESIGN OF STUDY: Hospital based observational study 
PERIOD OF STUDY :   one year ( june 2017 to may2018) 
METHODOLOGY: 
This is a cross sectional  study of  75 cases  of  HEMOPHILIA patients 
attending HEMOPHILIA TREATMENT CENTRE  and   those  getting 
admitted at medicine wards  in Coimbatore Medical College Hospital.   
INCLUSION CRITERIA  
1) All pts ≥ 13 yrs  of age. 
2) All cases of hemophilia A and hemophilia B 
 
EXCLUSION CRITERIA  
1)  Pts below 12 yrs of age.  
2)  Females and pregnant woman. 
3)  Consent not given. 
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4)  Patients having factor deficiency other than factor VIII and IX are 
excluded from the study 
5)  Patients with chronic liver disease 
6)  Patients on anticoagulant drugs 
An informed consent was taken from each patient before including into 
the study. the ethical committee of Coimbatore medical college hospital has 
given approval for this study protocol 
STUDY DETAILS 
A thorough clinical history was taken including, symptoms during 
presentation to hospital, history of prior admission and treatment done, age of 
onset of disease, history of consanguinity ,age of development of inhibitors and 
family history of bleeding disorders. Also took a note of history of transfusions 
and vaccination. 
The patients were then subjected to meticulous clinical examination and 
relevant blood investigations, radiological imaging for the study of disease 
.Blood investigations includes: 
1.  Coagulation profile   -Prothrombin time, activated partial thromboplastin 
time. 
2.  Viral markers   - HBsAg, HCV antibodies and HIV I & II antibodies. 
3. Functional independence and Disability assessment was done using 
FISH (Functional Independence Score in Haemophilia) . 
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Radiological imagings 
   x-ray, CT Scan or MRI of the joint most commonly involved in 
the patient or target joint, for purpose of radiological classification of 
Arthropathy 
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OBSERVATION AND RESULTS 
The data was analysed using the arithmetic mean, the standard deviation, 
standard error and correlation coefficient 75 cases of hemophila were studied 
and the results are tabulated as follows. 
TABLE 7 : AGE DISTRIBUTION 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
<20 29 39% 
20-40 40 53% 
>40 6 8% 
 
From the above table it can be observed that the maximum number of 
cases were between 20 to 40 years of age constituting 53% and minimum 
number of cases were in age group of above 40 years being 8%. In this data 
pediatric population less than 12 years were excluded. 
 
39%
53%
8%
GRAPH 1: SHOWING AGE DISTRIBUTION
<20
20-40
>40
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TABLE 8: SHOWING SEX DISTRIBUTION 
SEX NO OF PATIENTS PERCENTAGE 
MALE 75 100% 
FEMALE 0 0% 
All the patients under the study were male. Female haemophiliacs were 
not identified in the study population.  
 
 
 
 
 
7
5
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M A L E F E M A L E
GRAPH 2 :SEX DISTRIBUTION
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TABLE 9 :TYPE OF HAEMOPHILIA 
Among the study population 91% are haemophilia A and 9 % are 
haemophilia B.  
 
 
 
 
 
 
91%
9%
GRAPH 3 :TYPE OF HEMOPHILIA
HAEMOPHILIA A
HAEMOPHILIA B
TYPE NO OF PATIENTS PERCENTAGE 
HAEMOPHILIA A 68 91% 
HAEMOPHILIA B 7 9% 
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TABLE 10 :SHOWING SEVERITY OF HEMOPHILIA 
SEVERITY NO OF PATIENTS PERCENTAGE 
MILD 7 10% 
MODERATE 13 17% 
SEVERE 55 73% 
 
Among the study population 55(73%) cases belong to severe 
haemophilia followed 17 % and 10% of moderate  and mild haemophilia 
respectively.  
 
 
 
 
10%
17%
73%
GRAPH 4 :SEVERITY
MILD
MODERATE
SEVERE
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TABLE 11 : SHOWING CLINICAL MANIFESTATION 
 
The most common  complaint or manifestation  among hemophiliac was 
Joint Bleeding; it is seen in 70 patients followed muscular bleeding or muscular 
hematoma was the second most common manifestation seen in 39 patients 
followed by gum bleeding, gastrointestinal bleeding, genito urinary bleeding 
and others. The bar chart below shows the distribution of presenting 
manifestation. 
 
70
39
12
4 3 3 15
5
36
63 71 72 72 60
GRAPH 5 :CLINICAL MANIFESTATION
PRESENT ABSENT
CLINICAL MANIFESTATION PRESENT ABSENT 
JOINT BLEED 70 5 
MUSCULAR BLEED 39 36 
GUM BLEEDING 12 63 
GI BLEEDING 4 71 
GENITOURINARY 3 72 
CNS 3 72 
OTHERS 15 60 
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TABLE 12: FREQUENCY OF FACTOR REPLACEMENT 
FREQUENCY OF FACTOR  
REPLACEMENT (in a year) 
NO OF PATIENTS PERCENTAGE 
LESS THAN 15 20 27% 
MORE THAN 15 55 73% 
 
Among the study population ,20 patients requiring less than 15 
transfusions of clotting factor which is being 27% and most of the patients 
requires more than 15 times of  factor replacement in a year  which constitutes 
about 55 patients which is being 73% of total study population.  
 
 
27%
73%
GRAPH 6 :FREQUENCY OF FACTOR 
REPLACEMENT
LESS THAN 15
MORE THAN 15
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TABLE 13 : SHOWING CORRELATION BETWEEN FREQUNCY OF 
FACTOR REPLACEMENT AND SEVERITY OF HEMOPHILIA  
 
FACTOR REPLACEMENT – FREQUENCY 
SEVERITY MEAN SD 
MILD 2.85 1.21 
MODERATE 7.35 1.15 
SEVERE 21.69 3.66 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Above table shows correlation between frequency of factor replacement 
and severity of haemophilia which was statistically significant.  
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TABLE 14: SHOWING MOST COMMONLY AFFECTED JOINTS IN 
CASE OF HEMOPHILIA 
JOINT INVOLVEMENT NO OF PATIENTS PERCENTAGE 
ANKLE 14 29% 
KNEE 41 54% 
HIP 4 5% 
ELBOW 11 15% 
NOT INVOLVED 5 7% 
 
Analysis showed that the weight bearing joints – knees 54% and ankles 
29 % were most commonly affected. The other joints had a minor percentage 
contribution.  
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TABLE 15: AGE AT FIRST SYMPTOM 
AGE AT FIRST SYMPTOM NO OF PATIENTS PERCENTAGE 
< 5 YR 47 62% 
5-10 YR 20 27% 
>10 YR 8 11% 
 
From the above table it is clear that most of the study population 
presented with first symptom before the age of 5 years which is being 62% . 
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TABLE 16: PRIOR BLOOD TRANSFUSION 
PRIOR BLOOD TRANSFUSION NO OF PATIENTS PERCENTAGE 
YES 47 63% 
NO 28 37% 
About 47 patient from the study population gives previous history of 
blood transfusions which is about 63%.  
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TABLE 17: SHOWING HEPATITIS B VACCINATION STATUS  
HEP B VACCINATION NO OF PATIENTS PERCENTAGE 
DONE 35 47% 
NOT DONE 40 53% 
 
Thirty five patients were vaccinated for hepatitis B virus among the 75 
patients of study population.  
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TABLE 18: FAMILY HISTORY 
 
Being an inherited disorder, family history has been observed only in 
39%of  cases  among study population. 
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FAMILY HISTORY NO OF PATIENTS PERCENTAGE 
PRESENT 29 39% 
ABSENT 40 53% 
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TABLE 19 : PT AND APTT 
BLOOD PARAMETERS MEAN SD 
PROTHROMBIN TIME 12.47 1.96 
APTT 107.83 19.27 
 
APTT analysis showed an abnormal value (>40seconds) in about 100% 
of the study population. The prolonged aPTT signifies a clotting factor defect 
especially in the intrinsic and the common pathway. The Mean aPTT is 
107.83±19.27 seconds. 
 
TABLE 20 : H/O TRIVIAL TRAUMA REQUIRING FACTOR 
REPLACEMENT  
H/O TRAUMA (in a year) NO OF PATIENTS PERCENTAGE 
PRESENT 16 21% 
ABSENT 59 79% 
 
Among  the study population 16  (21%) cases had history of trivial 
trauma requiring factor replacement over a year. 
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TABLE 21: CONSAGUINITY 
CONSAGUINITY NO OF PATIENTS PERCENTAGE 
PRESENT 25 33% 
ABSENT 50 67% 
 
From the above table twenty five patients among 75 cases were born out 
of consanguity.  
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TABLE 22: TARGET JOINT 
TARGET JOINT NO OF PATIENTS PERCENTAGE 
YES 41 55% 
NO 34 45% 
 
At screening 55% (41/75) of these patients had target joints and 45% 
(34/75) had no target joint involvement. 
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TABLE 23: JOINT RADIOGRAPHY FOR HEMOPHILIC 
ARTHROPATHY 
JOINT RADIOGRAPHY FOR 
HEMOPHILIC ARTHROPATHY 
 (arnold hiltinger classification) 
NO OF 
PATIENTS 
PERCENTAGE 
STAGE 0 18 24% 
STAGE 1 13 17% 
STAGE 2 15 20% 
STAGE 3 25 34% 
STAGE 4 3 4% 
STAGE 5 1 1% 
 
From the cases with joint involvement about 25 (34%) cases out of 75 
hemophiliac are in stage 3 hemophililc arthropathy and only one case (1%)  is 
in stage 5 hemophilic arthropathy. 
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TABLE 24: INHIBITOR DEVELOPMENT 
INHIBITOR DEVELOPMENT NO OF PATIENTS PERCENTAGE 
PRESENT 15 20% 
ABSENT 60 80% 
MEAN AGE - 27.93 ± 11.97 
 
In this study, 20%(15/75) were positive for inhibitors and all were severe 
Haemophilia with Factor VIII levels less than 1%. 
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TABLE 25: TRANSFUSION RELATED INFECTIONS 
INFECTIONS PRESENT ABSENT PERCENTAGE 
HBSAG 9 66 10.22% 
HCV 5 70 5.35% 
HIV 0 75 00.00% 
 
In Table 25, are presented data for the TTI  in patients with hemophilia 
A and B, which shows that infection with HBV is found in a large group of 
patients 9(10.22%) out of  75 cases . But, infection with hepatitis virus B 
(HBV) found only in small number of cases 5(5.35%) .There were no patients 
with HIV infection. 
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TABLE 26: FUNCTIONAL INDEPENDENCE SCORE IN 
HEMOPHILIA ( FISH ) SCORING 
 
FISH SCORING NO OF PATIENTS PERCENTAGE 
LESS THAN 15 20 39% 
MORE THAN 15 55 53% 
 
From then above table 20 (39%) of cases of  haemophilia had  low 
functional independence score(FISH). Mean FISH score 22.22 ±8.73.  
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TABLE 27: SEVERITY VS JOINT RADIOGRAPHY 
 
SEVERITY 
JOINT RADIOGRAPHY MILD MODERATE SEVERE 
STAGE 0 7 11 0 
STAGE 1 0 2 11 
STAGE 2 0 0 15 
STAGE 3 0 0 25 
STAGE 4 0 0 3 
STAGE 5 0 0 1 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
From the above table there is statistically significant P<0.001 correlation 
between severity of haemophilia and staging of haemophilic arthropathy by 
joint radiography.  
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TABLE 28: JOINT RADIOGRAPHY AND TARGET JOINT   
 
TARGET JOINT 
JOINT RADIOGRAPHY YES NO 
STAGE 0 0 18 
STAGE 1 3 10 
STAGE 2 11 4 
STAGE 3 23 2 
STAGE 4 3 0 
STAGE 5 1 0 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
Above table shows statistically significant correlation between staging of 
haemophilic arthropathy by joint radiography and target joint involvement. 
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DISCUSSION 
 
 
This study was conducted in Coimbatore medical college hospital from 
July 2017 to July 2018. A total of 75 cases were studied. The clinical and 
diagnostic findings of this study are compared with our studies in literature 
here. 
In this study the most common type of hemophilia was hemophilia A  68 
cases (91%) as compared to hemophilia B. 
No Author 
Hemophilia A Hemophilia B 
CASES % CASES % 
1 Agarwal et al. 236/300 73.6% 64/300 21.4% 
2 Mishra S. et al. 68/77 88.3% 9/77 11.7% 
3 Parthiban et al. 41/50 82% 9/50 18% 
4 Rajendranigam et al. 224/254 86.15% 36/254 11.53% 
 
From the above table it is clear that hemophilia A is more common than 
hemophilia B which is similar to our present study.(87-89). No patients with 
hemophilia C is seen. In our study, age group of 20-40 years constituting of 
53% of study population. According to Parthiban et al age group predominantly 
affected was between 6-15 years 102 cases (40.16%) (88).  
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SEVERITY OF HEMOPHILIA 
NO AUTHOR SEVERE MODERATE MILD 
  CASES % CASES % CASES % 
1 Parthiban et al. 33/50  66%     13/50 26%    4/50    8% 
2 Mishra S et al 62/77 80.5%     6/77 7.8%   9/77    
11.7% 
3 Our study 55/75  73%     13/75  17%   7/75    10% 
 
Our finding of severity of Hemophilia correlates with the study 
conducted by Parthiban et al and Mishra S et al. 
     All the patients in our study population were male. Hemophilia is a X-linked 
hereditary disease, in which it manifest clinically only in males and female are 
being healthy carriers, female manifesting the disease is an extreme rarity. 
In our study population 47 out of 75 patients presented with  first onset 
of symptoms before the age of 5 years . In study conducted by Parthiban et al 
age of hemophilia A was ranging from 3
rd
 day of birth to 24   years with an 
average of 3.56 years and for hemophilia B it was 2nd  month  to 5.6 years with 
an average of 2.18 years (88).The age of onset of bleeding was less than 5 years 
in 77.6% of cases according to agarwal et al [87].  
Family history was seen only in 39% (29 out of 75 cases) in our study 
population. In study by Parthiban et al 52.2% of patients in study population 
had positive family history for hemophilia.  
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The most common complaint or manifestation  among hemophiliac was 
Joint Bleeding; it is seen in 70 patients followed muscular bleeding or muscular 
hematoma was the second most common manifestation seen in 39 patients 
followed by gum bleeding, gastrointestinal bleeding, genitourinary bleeding and 
others. Most common presentation according to Rajendra nigam et al was joint 
bleeding 64.96%, Followed by hematomas in muscle 19.68% and gum bleeding 
7.08% (88). In study by Parthiban et al most common presenting symptoms 
were hemarthrosis in about 79.10% of all hemophiliacs patients. 
Analysis from our study showed that the weight bearing joints – knees 
54% and ankles 29 % were most commonly affected in hemarthroses. The other 
joints had a minor percentage contribution. At screening 55% (41/75) of these 
patients had target joints and 45% (34/75) had no target joint involvement and 
most commonly involved joint in knee. From the study from mishra S et al 
Knee joint was involved in target joint involvement in nearly 57.1% of the 
patients.(87). 
According to rajendra nigam et al 110 out of 254 (43.30%) cases, the 
bleeds were trauma induced whereas most of patients experienced an 
spontaneous bleeds 144/254 (56.69%).(89) In our study, Among  the study 
population 16  (21%) cases had history of trivial trauma requiring factor 
replacement over a year. 
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In this study, 20% (15/75) were positive for inhibitors and all were 
severe Haemophilia with Factor VIII levels less than 1%. Patients  who had  
developed inhibitors has exposure to both cryoprecipitate/FFP and  plasma 
derived factor VIII.  In the study conducted by Parthiban et al inhibitors were 
found in 9.09% (4 out of 44 patients studied) (88). 
In our study 20 (39%) of cases of haemophilia had  low functional 
independence score(FISH). The mean FISH score in our study was 22.22±8.73 
which was comparatively similar to another study by A FERRERIA et al at the 
mean score of the FISH instrument was 25.64 (SD: 6.09). 7 out of 8 patients 
with mild hemophilia achieved the maximum functional independence score. 
There was no statistically significant difference between patients with severe 
and moderate hemophilia in terms of the mean functional independence 
score.(91). 
                                             HIV SEROPOSITIVITY 
No. Author Year No. Tested Positivity % 
1 Chow M.P 1991 11 82% 
2 Sengupta B et al 1992 37 24.3% 
3 Ghosh K. et al 2000 400 3.8% 
4 Gira P. Mankad  2010 232 00.00% 
5 Our study 2018 75 0% 
HIV can be transmitted  via clotting factors as well as plasma. However, 
there is been no documented case for these viruses being transmitted during  the 
replacement therapy in our study.. 
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HBSAG AND HCV SEROPOSITIVITY  IN HEMOPHILIC PATIENTS 
 
Out of 75 patients  HBsAg positivity was found in 9 patients and HCV 
seropositivity was found  in 5 patients. HCV seropositivity in hemophilic 
patients found to be varying from 100% to 0.43% in various studies. In our 
study  40 patients out of 75 were not immunized aganist Hepatitis B virus, 
among the unimmunized cases 9 patients were found to be HBsAg positive. In 
unimmunized Hemophiliacs prevalence of  Hepatitis B infection was 20% about 
five times more than general Indian population according to Chowdhury A et al 
(90). 
From the above tables it is clear that Transmission of viruses as been 
prevented by careful screening of blood donors, testing of donated blood 
products, treating donated blood products with a detergent and  heat  to destroy 
viruses. 
 
 
No Author Year No.of 
cases 
Hcv 
positivity 
HBsAg 
positive 
1 Chow MP et al 1991 11 100% 9% 
2 Ghosh k et al 2000 400 23.9% 6% 
3 Gira.p.mankad et al 2010 232 0.43% 0.43% 
4 Our study 2018 75 5.32% 10.22% 
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SUMMARY 
 
 
1.  In this study, hemophilia A was  68 cases (91%) was the most common 
type of hemophilia as compared to hemophilia B. 
2.  Age group of 20-40 years constituting of 53% of study population. 
3.  All the patients in our study population were male. 
4.  In our study population 47 out of 75 patients presented with  first onset of 
symptoms before the age of 5 years. 
5.  Family history was seen only in 39% (29 out of 75 cases) in our study 
population.  
6. The most common complaint or manifestation  among hemophiliac was 
Joint Bleeding; it is seen in 70 patients followed muscular bleeding or 
muscular hematoma was the second most common manifestation seen in 
39 patients followed by gum bleeding, gastrointestinal bleeding, 
genitourinary bleeding and others.  
7.  Analysis from our study showed that the weight bearing joints – knees 
54% and ankles 29 % were most commonly affected in hemarthroses. 
8.  16  (21%) cases had history of trivial trauma requiring factor replacement 
over a year. 
9.  20 (39%) of cases of  haemophilia had  low functional independence 
score(FISH). The mean FISH score in our study was 22.22±8.73. 
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10.  Out of 75 patients  HBsAg positivity was found in 9 patients and HCV 
seropositivity was found  in 5 patients. 
11.  20% (15/75) were positive for inhibitors and all were severe Haemophilia 
with Factor VIII levels less than 1%. 
12.  At screening 55% (41/75) of these patients had target joints and 45% 
(34/75) had no target joint involvement and most commonly involved 
joint in knee. 
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CONCLUSION 
 
Hemophilia is a X linked recessive disorder is the most common 
hereditary coagulation disorder seen by physicians. Most of the affected were 
being males with females being affected is rarity. Hemophilia A is more 
common than Hemophilia B. 
Most of the patients with the disease usually manifest in first decade of 
life, as prolonged bleeding or hematomas due to any trauma. Majority of them 
have family history of bleeding disorder but it is not a rule in all the cases .Most 
common presenting complaint is joint bleeding followed by muscular 
hematomas, gum bleeding, Gl bleeding and genitourinary bleeding. Majority of 
the patients had severe form of the disease. Recurrent bleeding into joint 
progresses to chronic progressive hemophilic arthropathy, immobility due to 
pain worsens the disease so patients with hemophilic arthropathy must be 
educated  about importance of  early recognition and  role of physiotherapy in 
preventing arthropathy. 
Patients with hemophilia require multiple transfusions during the 
episodes of bleeding. Diagnosis poses little difficulty due to improved 
awareness and introduction of better laboratory tests. Treatment of hemophilia 
was greatly improved by introduction of pure viral inactivated factor 
replacements and recombinant factors. Transfusion related viral infections like 
HIV, HBV, HCV and other minor viruses are still a major hazard especially 
seen in older persons with hemophilia treated before 1985. 
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Recombinant factor replacements negate complications of transmission 
of viral infections but development of inhibitors against specific factors is a 
growing concern. Inhibitors for factor VIII and factor IX can be treated by 
immune tolerance therapy and prophylactic factor replacements. Prophylactic 
factor replacement must be advised in selected patients whenever pure and 
sterile factor replacements are available. 
In a resource constraint country like India recombinant factor is not 
readily accessible due to cost factor and lack of awareness among the patients. 
Still plasma, cryoprecipitates and plasma derived factors are used many a times 
during bleeding episodes, so treatment options used and available are not 
completely safe. Better screening practices of blood products and continuous 
monitoring of blood banks to prevent any blood transmitted infections. All 
patients need to be educated about transfusion related hazards and preventive 
measures must be advised, especially HBV vaccination. Opening up of more 
hemophilia treatment centres and  home based self administration of factors 
would help the persons with hemophilia to avoid joint damage and disability. 
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PROFORMA 
Name : 
Address : Age/ Sex : 
Occupation : 
DOA : DOD : 
Chief complaints with duration 
1. Site of bleeding 
2. Duration 
3. Onset and progression 
4. Severity 
5. H/O trauma 
6. Joint swelling or muscular swelling 
Past history 
1. Age at time of  first symptom of  hemophilia and presenting symptom 
2. H/O Tuberculosis 
3. H/O Surgery 
4. H/O Previous admission 
5. H/O Factor or blood transfusion 
6. H/O Jaundice 
7. H/O similar complaints 
8. H/O Hepatitis B vaccination 
Family history 
1. H/O DM / HTN 
2. H/O TB 
3. H/O Bleeding disorder 
4. H/O Consanguineous marriage 
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Personal history  
1. Diet  
2. Sleep 
3. Bowel/ Bladder 
4. Smoker / Alcoholic 
GENERAL PHYSICAL EXAMINATION 
1. Obese / Not obese 
2. Nutritional status; Poor / Avg / Good 
3. Pallor  
4. Icterus 
5. Cyanosis / Clubbing 
6. Oral cavity 
7. General – Lymphadenopathy 
8. PR 
9. BP 
SYSTEMIC EXAMINATION 
1. Cardiovascular system 
2. Respiratory system 
3. Central Nervous System 
4. Abdomen  
5. Musculoskeletal. 
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CONSENT FORM 
 
           Yourself Mr/ Mrs /Ms…………………………….......………………...... 
are being asked  to be a participant in the research study titled "CLINICAL 
PROFILE OF HEMOPHILIA PATIENTS AND ASSESSMENT OF 
THEIR QUALITY OF LIFE” in CMC Hospital, Coimbatore, conducted by 
Dr.RAM PRAKASH. S., Post Graduate Student in The Department of General 
Medicine, Coimbatore Medical College. You satisfy eligibility as per the 
inclusion criteria. You can ask any question you may have before agreeing to 
participate. 
Research Being Done 
      Clinical profile of hemophilia patients and assessment of their quality of life 
Purpose of Research 
 To evaluate clinical profile of patients with hemophilia. 
 To find prevalence of  HIV, Hepatitis B and Hepatitis C in hemophiliacs. 
 To assess their quality of life 
Procedures involved 
         The research includes detailed clinical examination including medical 
history, physical examination with reference to the indication of admission. 
Physical examination involves general and systemic examination. Measurement 
of limb and joints in case of musculoskeletal bleeding. Blood  investigation for 
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bleeding profile, liver function test HIV antibodies, serum HBsAg and HCV 
antibodies. Radiological investigations like X-ray and ultrasound. 
Decline from Participation 
You have the option to decline from participation in the study existing 
protocol for your condition. 
Privacy and Confidentiality 
          Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
Authorization to publish Results 
         Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified. 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to me, and 
I may ask questions at any time. 
 
Signature /left thumb impression     Date :  
(volunteer) 
 
Signature of witness       Date : 
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FISH 
 
 
FISH (Functional Independence Score for patients with Hemophilia) has 
been developed as a measure of disability in patients with hemophilia.. It can be 
used to evaluate change in functional independence over time, or after a 
therapeutic intervention. 
The FISH is meant to complement other scores that measure body 
structure and function such as the clinical joint evaluation score, and the 
radiological score. 
The scores that are achieved in each task are summed and  giving a total 
from 8 to 32 points with 32 indicating  highest level of functional independence 
score. 
LEVELS OF FUNCTION AND THEIR SCORES 
 
4. The subject is able to perform the activity without any difficulty like other 
healthy peers. 
3. The subject is able to perform the activity without aids or assistance, but 
with slight discomfort. He is unable to perform the activity like his healthy 
peers. 
2. The subject needs partial assistance/ aids/ modified instruments/ modified 
environment to perform the activity. 
1. The subject is unable to perform the activity, or needs complete assistance 
to perform the activity. 
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EATING AND GROOMING 
 (A) EATING 
Activity 
Serve the meal with appropriate utensils and implements and observe the 
subject‘s ability to mix and lift the food to his mouth using hands or 
implements. 
Scoring 
Score 4 if the subject: 
− has no difficulty in performing the activity. 
 Score 3 if the subject: 
− has to lean over unnaturally to reach his food due to limitation of flexion of 
the elbow/ has to take several breaks in between due to pain. The subject is 
not to be asked if he has pain, but is to be observed to see if he has any 
discomfort. 
− has no difficulty performing the activity with a prosthesis, using 
implements commonly used in his community. 
Score 2 if the subject: 
− uses implements that are not commonly used in his community e.g. spoon 
or a fork in a community where other members use their hand OR uses 
modified utensils/implements to feed himself. 
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− has difficulty feeding himself using a prosthesis, or uses implements that 
are not commonly used in his community. 
− is a right-handed individual, but has to eat with his left hand due to 
problems with the right upper limb. 
        Score 1 if the subject: 
− is unable to feed himself. 
 
(B) GROOMING 
 Grooming includes oral care, hair grooming, washing hands and face. 
Shaving is optional. 
Activity 
 
 Place the subject in front of a sink and place a toothbrush and toothpaste, 
comb and other culturally appropriate instruments on a table close to the 
subject. 
Scoring 
Score 4 if: 
 
− the subject has no difficult in grooming. / the child needs assistance only 
to apply the toothpaste on the brush. 
Score 3 if the subject 
− adopts abnormal postures to comb the back of his head/ shave/ wash his 
face. 
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− experiences pain or discomfort while grooming (as assessed by the 
observer) / takes an unnaturally long time to perform the activity. 
Score 2 if the subject 
− is not able to comb hair in all areas of the head -the back /side of the head 
/ requires any modified instrument. 
− is a right-handed individual, but uses the left hand for grooming, due to 
problems with the right upper limb 
Score 1 if the subject 
− is unable to do the activity because of problems with reach. 
Score the lowest of either eating/grooming for this activity. 
(C)BATHING 
Activity 
This activity assesses the ability to wash, soap, and dry different parts of 
the body –  including the perineal region, and feet (except the back).  
It is essential to assess the reach on both sides of the body, using both 
hands. 
Assess the: 
 
• ability to turn on/off a tap or ability to lift a mug of water from the floor to 
above the head 
• ability to pick up a 75 gms bar of soap from the floor . 
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• ability to take the bar of soap to the feet, shin, thigh, perineum, abdomen  
and nape of the neck 
Scoring 
Score 4 if the subject: 
 
− has no difficulty in bathing. 
 
Score 3 if the subject: 
 
− adopts unusual postures while bathing e.g. Places feet on a stool to apply 
 soap/ is in discomfort while performing the activity 
Score 2 if: 
 
− the subject requires a shower instead of water from a bucket in a 
community where the other members use water from a bucket (modified 
environment); but if others in the community too use the shower, score 4. 
− the bathtub or bathroom has to be modified (modified environment.)/the 
subject sits on a stool for his bath (modified environment.) 
− the subject has to use instruments to reach any part of the body (except the 
back). 
− the subject requires occasional help to bathe and dry the feet, perineum, or 
any other part of the body, except the back. 
Score 1 if: 
 
- the subject requires a bed bath, or is unable to perform most of the activity 
of bathing/ drying. 
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(D)DRESSING 
Activity 
Place a shirt, T shirt/vest, trouser, socks, prosthesis /orthosis (if any) in 
front of the subject. 
Scoring 
Score 4 if the subject: 
 
− is able to get dressed without discomfort and without assistance. 
 
Score 3 if the subject: 
 
− experiences discomfort during the activity. [Assess the activity using an 
open shirt with buttons, and a T-shirt or vest]. 
− takes momentary support from the wall/ table to steady himself while 
donning his trousers/ uses adaptive maneuvers to don the shirt due to 
discomfort. 
− takes a long time to put on his shirt/ T shirt/ vest/ trouser 
Score 2 if the subject: 
 
− requires help to wear the trouser.  
− requires an aid such as a trouser puller.  
− sits to put on his trousers (aid).  
− requires considerable amount of support from the wall/ table while 
donning trousers. 
− needs help with his upper buttons (requires partial assistance). 
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− requires complete help in <50% of the activity, e.g. – partial assistance in 
 donning the trouser, but no help required in putting on the shirt. If however,  
 requires assistance in donning both shirt and trouser, score 1. 
 
Score 1 if the subject 
 
− requires help in >50% of the activity. 
 
If the subject has to sit only to put on/take off his socks- score 4. 
(E) CHAIR TRANSFER 
Activity 
Place a chair with armrests of an appropriate height in front of the 
subject (i.e. the patient sits comfortably with hips and knees flexed to 95 
degrees, with feet on the ground – 18 inch for adults). Ask the subject to appose 
his palms (as in a Namaste/ prayer posture), get up from the chair, and then sit 
down. 
Scoring 
Score 4 if the subject: 
 
− has no difficulty in performing the above activity. 
 
Score 3 if the subject: 
 
− leans excessively forward in order to get up/ sits with one or both knee 
joints slightly extended, but does not require support to get up. 
− uses momentary support of the arm rest while getting up 
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Score 2 if the subject: 
 
− requires a lot of support from the armrest to get up./requires the use of 
crutches to get up. 
Score 1 if the subject: 
 
− is not able to get up from the chair. 
 
(F) SQUATTING 
Activity 
This assesses the ability to squat on the floor and rise to an erect posture. 
 
Scoring 
Score 4 if the subject: 
 
− has no difficulty in performing the activity. 
 
Score 3 if the subject: 
 
− is able to squat to a height of 8-12 inches (6-10 for children).  
− is able to squat to a height of 8 inches, with one leg in extension (6inches 
for children). 
− is able to squat to a height of 8-12 inches (6-10 for children) using 
momentary support from the side/floor 
Score 2 if the subject: 
 
− is able to squat to a height of 8-12 inches (6-10 for children) with maximum 
support from a chair/grab-rail. 
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Score 1 if the subject: 
− is not able to squat to a height of 12 inches with support from the side (10 
inches for children). 
(G) WALKING PATTERN 
 
Activity 
Walking is to be assessed over a distance of 10 meters. There has to be a 
good heel to toe pattern in the gait, with steps of relatively equal length and 
cadence. Heel strike should be with knee in full extension. The knee should 
bend adequately during stance and swing phase. There should not be an obvious 
limp. 
Scoring 
 
Score 4 if the subject 
 
− has an apparently normal gait. 
 
Score 3 if the subject 
 
− has a stiff knee gait/ limp. If stance phase in a limb is reduced due to pain -
 score 3 
Score 2 if the subject 
 
− uses a cane/walking stick or uses a knee/ankle brace 
 
Score 1 if the subject 
 
− is unable to walk 10 meters. 
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(H) STAIR CLIMBING 
Activity 
Place the subject in front of a flight of stairs with banisters/side rails. Ask 
him to climb up and down the stairs slowly.  
Score 4 if the subject 
 
− is able to climb up/down the stairs without a limp or aid with an 
alternating stepping pattern. He should be able to climb up/down the steps 
in less than 9 seconds (in either directions). 
 
Score 3 if the subject 
 
− has a limp/discomfort while climbing the steps. If he uses the rails for 
occasional minimal support – he should be able to climb up/down the 
steps within 14 seconds (in either direction). 
 
− climbs up the stairs, taking one step at a time or climbs down the stairs, 
taking one step at a time 
Score 2 if the subject 
 
− takes more than 14 seconds to climb up/down the stairs using the aid of 
the rails or crutches/ assistance of a helper(in either direction). 
Score 1 if the subject 
 
− is unable to climb 14 steps. 
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(I) RUNNING 
Running is to be assessed over a distance of 25 meters for children, and 
50 meters for adults (age 15 years and above). There should be periods during 
which both feet are off the ground. 
Scoring 
 
Score 4 if the subject: 
 
− has no difficulty/discomfort while running. 
 
Score 3 if the subject: 
 
− has pain/discomfort while running or  able to run only part of the distance. 
 
Score 2 if the subject: 
 
− is not able to run, but is able to walk briskly (>70meters/min for children, 
and >100 meters/minute for adults). 
Score 1 if the subject: 
− is not able to walk briskly (<70meters/min for children, and <100 
meters/minute for adults). 
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ஒப்புதல் படிவம் 
 
பெயர்  : 
 
வயது  : 
 
ொலினம்  : 
 
 முகவாி : 
  
 
 
ககாவவ அரசு மருத்துவக்கல்லூாி மருத்துவமவனயில் மருத்துவர்                
br. uhk;gpufh#; தவலவமயில் நடைபபறும் இந்த ஆய்வில் முழு சம்மதத்துடன் 
கலந்துபகொள்ள சம்மதிக்கிறேன். இந்த ஆய்வில் என்டை ெற்றி விவரங்கவள 
ொதுகாப்புடன் இந்த ஆய்வில்  பவளியிட ஆட்றசபடை இல்டல என்று  பதரிவித்துக் 
பகொள்கிறேன்  .எந்த றநரத்திலும் ஆய்வில் இருந்து எந்த றநரத்திலும் விலக்கிக்பகொள்ளும்  
உரிடம உண்டு என்று அேிறவன் . 
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